Physiologically balanced injectable formulations of fosnetupitant
Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
1. A pharmaceutically stable injectable liquid formulation of fosnetupitant comprising:
a) from 2.3 to 30 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) from 5 to 50 μg/mL palonosetron hydrochloride based on the weight of the free base;
c) sodium hydroxide;
d) disodium edetate;
e) optionally hydrochloric acid; and
f) mannitol.
2. A pharmaceutically stable injectable lyophilized formulation of fosnetupitant comprising:
a) from 2.3 to 30 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) from 5 to 50 μg/mL palonosetron hydrochloride based on the weight of the free base;
c) sodium hydroxide;
d) disodium edetate;
e) optionally hydrochloric acid; and
f) mannitol.
3. A pharmaceutically stable liquid injectable solution formulation of fosnetupitant at a pH of 7.0-10.0 comprising:
a) from 2.3 to 30 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) from 5 to 50 μg/mL palonosetron hydrochloride based on the weight of the free base;
c) from 0.05 to 0.9 mg/mL disodium edetate;
d) from 10 to 100 mg/mL mannitol;
e) NaOH;
optionally HCl; and
g) water q.s.
4. A pharmaceutically stable lyophilized powder injectable formulation of fosnetupitant at a pH of 7.0-10.0 comprising:
a) from 2.3 to 30 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) from 5 to 50 μg/mL palonosetron hydrochloride based on the weight of the free base;
c) from 0.1 to 2.0 mg/mL disodium edetate;
d) from 10 to 100 mg/mL mannitol; and
e) NaOH and optionally HCl;
based on a reconstitution in a suitable water volume.
5. The lyophilized powder formulation of claim 4 at a pH of 7.0-10.0, comprising:
a) from 2.3 to 30 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) from 5 to 50 μg/mL palonosetron hydrochloride based on the weight of the free base;
c) from 0.1 to 2.0 mg/mL disodium edetate;
d) from 10 to 100 mg/mL mannitol; and
e) NaOH and HCl;
based on a reconstitution in a suitable water volume.
6. The lyophilized powder formulation of claim 4 at a pH of 8.5-9.5, comprising:
a) about 13.0 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) about 14.04 μg/mL palonosetron hydrochloride based on the weight of the salt;
c) about 0.32 mg/mL disodium edetate;
d) about 38 mg/mL mannitol; and
e) NaOH and optionally HCl;
based on a reconstitution in water volume of 20 mL.
7. A method of manufacturing a liquid injectable or lyophilized formulation of fosnetupitant comprising:
a) simultaneously admixing the chloride hydrochloride salt of fosnetupitant with sodium hydroxide in water at a basic pH of from approximately 11 to 14 to form a solution;
b) reducing the pH of the solution to a basic pH of from approximately 7 to 10 by the addition of one or more acidic pH adjusting agents; and
c) optionally admixing the solution with one or more pharmaceutically acceptable excipients.
8. An intravenous formulation of fosnetupitant made by a process of mixing the fosnetupitant formulation of claim 2 with 0.9% saline or 5% glucose.
9. The liquid formulation of claim 1 comprising palonosetron hydrochloride and HCl.
10. The liquid formulation of claim 3 , comprising:
a) from 2.3 to 30 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) from 5 to 50 μg/mL palonosetron hydrochloride based on the weight of the free base;
c) from 0.1 to 2.0 mg/mL disodium edetate;
d) from 10 to 100 mg/mL mannitol; and
e) NaOH and HCl.
11. The liquid formulation of claim 3 at a pH of 8.5-9.5, comprising:
a) about 13.0 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) about 14.04 μg/mL palonosetron hydrochloride based on the weight of the salt;
c) about 0.32 mg/mL disodium edetate;
d) about 38 mg/mL mannitol; and
e) NaOH and HCl.
12. The lyophilized powder formulation of claim 2 comprising:
a) from 2.3 to 30 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) from 5 to 50 μg/mL palonosetron hydrochloride based on the weight of the free base;
c) from 0.1 to 2.0 mg/mL disodium edetate;
d) from 10 to 100 mg/mL mannitol; and
e) NaOH and optionally HCl;
based on a reconstitution in a suitable water volume.
13. The lyophilized powder formulation of claim 2 comprising:
a) about 13.0 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) about 14.04 μg/mL palonosetron hydrochloride based on the weight of the salt;
c) about 0.32 mg/mL disodium edetate;
d) about 38 mg/mL mannitol; and
e) NaOH and HCl;
based on a reconstitution in a suitable volume of water.
14. The liquid formulation of claim 1 at a pH of from 7.5 to 10.0.
15. The lyophilized powder formulation of claim 2 having a pH of from 7.5 to 10.0 upon reconstitution in water.
16. The lyophilized powder formulation of claim 12 having a pH of from 7.5 to 10.0 upon reconstitution in water.
17. The lyophilized powder formulation of claim 13 having a pH of from 7.5 to 10.0 upon reconstitution in water.
18. The method of claim 7 , wherein the acidic pH adjusting agent comprises hydrochloric acid.
19. A pharmaceutically stable injectable liquid formulation of fosnetupitant comprising:
a) from 2.3 to 30 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) from 5 to 50 μg/mL palonosetron hydrochloride based on the weight of the free base;
c) an alkalizing agent; and
d) an alkaline pH.
20. The pharmaceutically stable injectable liquid formulation of claim 19 comprising:
a) about 13.0 mg/mL of the chloride hydrochloride salt of fosnetupitant;
b) about 14.04 μg/mL palonosetron hydrochloride based on the weight of the salt;
c) sodium hydroxide as the alkalizing agent; and
d) a pH of from 7 to 10.
21. The pharmaceutically stable injectable liquid formulation of claim 19 comprising sodium hydroxide as the alkalizing agent and a pH of from 7 to 10.